The NKG2D - IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies

Oncotarget

Volumn 6, Issue 41, 2015, Pages 43230-43243

  Ruck, Tobias ^a   Bittner, Stefan ^b   Afzali, Ali Maisam ^a   Göbel, Kerstin ^a   Glumm, Sarah ^a   Kraft, Peter ^c   Sommer, Claudia ^c   Kleinschnitz, Christoph ^c   Preube, Corinna ^d   Stenzel, Werner ^d   Wiendl, Heinz ^a   Meuth, Sven G ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Idiopathic inflammatory myopathies; IL 15; NKG2D; Pathology Section; Polymyositis; T cell activation

Indexed keywords

CREATINE KINASE; INTERLEUKIN 15; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN SMICA; UNCLASSIFIED DRUG; IL15 PROTEIN, HUMAN; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOLYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MACROPHAGE; MALE; MUSCLE BIOPSY; MYOBLAST; POLYMYOSITIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UPREGULATION; AGED; CELL CULTURE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; MYOSITIS; PATHOLOGY; POLYMERASE CHAIN REACTION;

ADULT; AGED; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INTERLEUKIN-15; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYOBLASTS; MYOSITIS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84952926857     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6462     Document Type: Article

References (51)

1. Zong M and Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol. 2011; 7(5):297-306.
2. Dalakas MC. Update on the molecular pathogenesis of inflammatory myopathies. Autoimmun Rev. 2004; 3 Suppl 1:S37-39.
3. Emslie-Smith AM, Arahata K and Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cellmediated cytotoxicity in myopathies. Hum Pathol. 1989; 20(3):224-231.
4. Dalakas MC and Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003; 362(9388):971-982.
5. Venalis P and Lundberg IE. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford). 2014; 53(3):397-405.
6. Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E, Nennesmo I, Malmberg KJ, Soderberg-Naucler C, Trollmo C, Lundberg IE and Malmstrom V. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol. 2009; 183(7):4792-4799.
7. Pandya JM, Fasth AE, Zong M, Arnardottir S, Dani L, Lindroos E, Malmstrom V and Lundberg IE. Expanded T cell receptor Vbeta-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum. 2010; 62(11):3457-3466.
8. Malmstrom V, Venalis P and Albrecht I. T cells in myositis. Arthritis research & therapy. 2012; 14(6):230.
9. Wiendl H, Hohlfeld R and Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 2005; 26(7):373-380.
10. Wiendl H, Mitsdoerffer M, Schneider D, Chen L, Lochmuller H, Melms A and Weller M. Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB J. 2003; 17(13):1892-1894.
11. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Weiss EH, Dichgans J, Lochmuller H, Hohlfeld R, Melms A and Weller M. The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain. 2003; 126(Pt 1):176-185.
12. Groh V, Smythe K, Dai Z and Spies T. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol. 2006; 7(7):755-762.
13. Ruck T, Bittner S, Gross CC, Breuer J, Albrecht S, Korr S, Gobel K, Pankratz S, Henschel CM, Schwab N, Staszewski O, Prinz M, Kuhlmann T, Meuth SG and Wiendl H. CD4+NKG2D+ T cells exhibit enhanced migratory and encephalitogenic properties in neuroinflammation. PLoS One. 2013; 8(11):e81455.
14. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL and Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science. 1999; 285(5428):727-729.
15. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003; 3(10):781-790.
16. Gonzalez S, Lopez-Soto A, Suarez-Alvarez B, Lopez-Vazquez A and Lopez-Larrea C. NKG2D ligands: key targets of the immune response. Trends Immunol. 2008; 29(8):397-403.
17. Ehrlich LI, Ogasawara K, Hamerman JA, Takaki R, Zingoni A, Allison JP and Lanier LL. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol. 2005; 174(4):1922-1931.
18. Nausch N and Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008; 27(45):5944-5958.
19. Verneris MR, Karami M, Baker J, Jayaswal A and Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 2004; 103(8):3065-3072.
20. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, Raulet DH, Lanier LL, Groh V, Spies T, Ebert EC, Green PH and Jabri B. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity. 2004; 21(3):357-366.
21. Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, Verkarre V, Fodil N, Bahram S, Cerf-Bensussan N and Caillat-Zucman S. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity. 2004; 21(3):367-377.
22. West EJ, Scott KJ, Jennings VA and Melcher AA. Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. Br J Cancer. 2011; 105(6):787-795.
23. Fagan EA and Eddleston AL. Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells. Gut. 1987; 28(2):113-116.
24. Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC and Jabri B. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol. 2001; 167(10):5527-5530.
25. Steinle A, Li P, Morris DL, Groh V, Lanier LL, Strong RK and Spies T. Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics. 2001; 53(4):279-287.
26. Eagle RA, Traherne JA, Hair JR, Jafferji I and Trowsdale J. ULBP6/RAET1L is an additional human NKG2D ligand. Eur J Immunol. 2009; 39(11):3207-3216.
27. Salih HR, Rammensee HG and Steinle A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol. 2002; 169(8):4098-4102.
28. Salih HR, Goehlsdorf D and Steinle A. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol. 2006; 67(3):188-195.
29. Saikali P, Antel JP, Newcombe J, Chen Z, Freedman M, Blain M, Cayrol R, Prat A, Hall JA and Arbour N. NKG2Dmediated cytotoxicity toward oligodendrocytes suggests a mechanism for tissue injury in multiple sclerosis. J Neurosci. 2007; 27(5):1220-1228.
30. Groh V, Bruhl A, El-Gabalawy H, Nelson JL and Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci U S A. 2003; 100(16):9452-9457.
31. Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, Caillat-Zucman S, Paul P, Gornet JM, Douay C, Ravet S, Tamouza R, Charron D, Lemann M, Mayer L and Toubert A. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology. 2007; 132(7):2346-2358.
32. Dejaco C, Duftner C, Al-Massad J, Wagner AD, Park JK, Fessler J, Aigelsreiter A, Hafner F, Vega S, Sterlacci W, Grubeck-Loebenstein B, Tzankov A, Ness T, Boiardi L, Salvarani C and Schirmer M. NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. Ann Rheum Dis. 2013; 72(11):1852-1859.
33. Champsaur M and Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010; 235(1):267-285.
34. Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, Furst D, Mytilineos J, Kalthoff H, Janssen O, Oberg HH and Kabelitz D. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17. Int J Cancer. 2013; 133(7):1557-1566.
35. Dehmel T, Janke A, Hartung HP, Goebel HH, Wiendl H and Kieseier BC. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiol Dis. 2007; 25(3):665-674.
36. Borthwick NJ, Lowdell M, Salmon M and Akbar AN. Loss of CD28 expression on CD8(+) T cells is induced by IL-2 receptor gamma chain signalling cytokines and type I IFN, and increases susceptibility to activation-induced apoptosis. Int Immunol. 2000; 12(7):1005-1013.
37. Traitanon O, Gorbachev A, Bechtel JJ, Keslar KS, Baldwin WM, 3rd, Poggio ED and Fairchild RL. IL-15 induces alloreactive CD28(-) memory CD8 T cell proliferation and CTLA4-Ig resistant memory CD8 T cell activation. Am J Transplant. 2014; 14(6):1277-1289.
38. Gagnon J, Ramanathan S, Leblanc C, Cloutier A, McDonald PP and Ilangumaran S. IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes. J Immunol. 2008; 180(12):7958-7968.
39. Budagian V, Bulanova E, Paus R and Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006; 17(4):259-280.
40. Dalakas MC. Inflammatory muscle diseases. N Engl J Med. 2015; 372(18):1734-1747.
41. Sugiura T, Harigai M, Kawaguchi Y, Takagi K, Fukasawa C, Ohsako-Higami S, Ohta S, Tanaka M, Hara M and Kamatani N. Increased IL-15 production of muscle cells in polymyositis and dermatomyositis. Int Immunol. 2002; 14(8):917-924.
42. Zong M, Loell I, Lindroos E, Nader GA, Alexanderson H, Hallengren CS, Borg K, Arnardottir S, McInnes IB and Lundberg IE. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor alpha expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis. 2012; 71(6):1055-1063.
43. Andersson AK, Sumariwalla PF, McCann FE, Amjadi P, Chang C, McNamee K, Tornehave D, Haase C, Agerso H, Stennicke VW, Ahern D, Urso B, Trowsdale J, Feldmann M and Brennan FM. Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis. Arthritis Rheum. 2011; 63(9):2617-2629.
44. Zaguia F, Saikali P, Ludwin S, Newcombe J, Beauseigle D, McCrea E, Duquette P, Prat A, Antel JP and Arbour N. Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple sclerosis. J Immunol. 2013; 190(6):2510-2518.
45. Schreiner B, Voss J, Wischhusen J, Dombrowski Y, Steinle A, Lochmuller H, Dalakas M, Melms A and Wiendl H. Expression of toll-like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates IL-8 release and upregulation of NKG2D-ligands. FASEB J. 2006; 20(1):118-120.
46. Mielnik P, Chwalinska-Sadowska H, Wiesik-Szewczyk E, Maslinski W and Olesinska M. Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity. Rheumatol Int. 2012; 32(3):639-643.
47. Broux B, Mizee MR, Vanheusden M, van der Pol S, van Horssen J, Van Wijmeersch B, Somers V, de Vries HE, Stinissen P and Hellings N. IL-15 amplifies the pathogenic properties of CD4+CD28-T cells in multiple sclerosis. J Immunol. 2015; 194(5):2099-2109.
48. Saikali P, Antel JP, Pittet CL, Newcombe J and Arbour N. Contribution of astrocyte-derived IL-15 to CD8 T cell effector functions in multiple sclerosis. J Immunol. 2010; 185(10):5693-5703.
49. Wiendl H, Mitsdoerffer M, Schneider D, Melms A, Lochmuller H, Hohlfeld R and Weller M. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain. 2003; 126(Pt 5):1026-1035.
50. Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, Vencovsky J, de Visser M and Hughes RA. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004; 14(5):337-345.
51. Groh V, Wu J, Yee C and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002; 419(6908):734-738.